Smith & Nephew's Study Outcomes For REGENETEN Encouraging
Zacks Investment Research | Nov 19, 2019 08:39PM ET
Smith & Nephew (LON:SN) plc (NYSE:SNN) , recently announced favorable outcome of a clinical study evaluating its REGENETEN Bioinductive Implant in the treatment of large (3-5cm) and massive (5cm+) rotator cuff tears.
This development highlights the company’s commitment toward strengthening its Global Sports Medicine business segment.
About the Study
The prospective, non-comparative arm study of the REGENETEN implant, conducted across 23 patients suffering from large and massive tears in the United States, highlighted a 96% tendon healing rate at two years. No significant difference was found between the treatments of primary repairs and revision surgery.
This study offers strong evidence in favor of REGENETEN as a suitable treatment option, which can cover the entire range of tears from partial to large and massive ones.
Tendon healing was evaluated by consecutive ultrasound examinations to 24 months and a single post-operative MRI. Tendon thickness was observed to have increased from three months to 12 months before marginally diminishing at 24 months. This was indicative of the functional remodeling of the new tissue. No implant-related adverse events took place as a result of the use of the REGENETEN Bioinductive Implant.
The REGENETEN Bioinductive Implant is currently available in the United States.
Recent Developments
Lately, the company has been conducting crucial research studies that have bolstered its Global Sports Medicine segment.
In October 2019, Smith & Nephew announced favorable results for its NOVOSTITCH Meniscal Repair System demonstrating one-year results of the STITCH Study. The NOVOSTITCH Meniscal Repair System caters to complex meniscal tear patterns not properly served by other repair systems currently available in the market. The STITCH Study is the first prospective clinical trial to assess the proficiency of repairing Horizontal Cleavage Tears - one of the most common meniscal tears that affects nearly one-third of patients with this injury.
Price Performance
In a year's time, shares of Smith & Nephew have gained 19.5% compared with the Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.